Primary Resistance to PD-1-Based Immunotherapy—A Study in 319 Patients with Stage IV Melanoma

Background: Primary resistance to immunotherapy can be observed in approximately 40–65% of the stage IV melanoma patients treated with immune checkpoint inhibitors. A minority of the patients receive a second-line therapy, and the clinical benefit is small. Patients and methods: Stage IV melanoma pa...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancers (Basel)
Main Authors: Amaral, Teresa, Seeber, Olivia, Mersi, Edgar, Sanchez, Stephanie, Thomas, Ioannis, Meiwes, Andreas, Forschner, Andrea, Leiter, Ulrike, Eigentler, Thomas, Keim, Ulrike, Garbe, Claus
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7226601/
https://ncbi.nlm.nih.gov/pubmed/32331243
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12041027
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados